Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCJ2 mRNA vaccine
- Development stage
- Preclinical
- Lead developer
- Texas Children's Hospital Center for Vaccine Development
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
TCJ2 mRNA vaccine is an experimental lipid nanoparticle (LNP)-formulated mRNA vaccine candidate designed for the prevention and treatment of Chagas disease, which is caused by the protozoan parasite *Trypanosoma cruzi*. Identified through mass spectrometry-based immunopeptidomics, the vaccine encodes the Tcj2 protein, a highly conserved trypanosome chaperone protein belonging to the DnaJ (heat shock protein 40) family. In preclinical murine models, the vaccine has been shown to elicit robust antigen-specific CD8+ cytotoxic T cell responses and a Th1-skewed humoral antibody response, which significantly restricts *T. cruzi* replication in vitro without cross-reacting with human or mouse DnaJ orthologs.
- Other names
- Tcj2 mRNA vaccineTcj-2 mRNA vaccineTcj 2 mRNA vaccineTcj2 mRNA-LNP vaccineTcj-2 mRNA-LNP vaccineTcj 2 mRNA-LNP vaccine
Beyond the preview
Go deeper on TCJ2 mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCJ2 mRNA vaccine.